Dusa signs patent licensing agreement with River’s Edge

The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license. As part of the agreement, Dusa will receive a share of the net revenues River’s Edge generates.

Previously, Dusa and River’s Edge have signed a settlement and mutual release to settle patent litigation, which is being amended to accommodate this new patent license agreement.

Dusa is taking this action in light of the entry of generic products in this market and the company’s need to enforce its intellectual property rights while trying to avoid litigation. Dusa, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the FDA.

Bob Doman, president and CEO of Dusa, said: “Dusa is pleased to have reached this new patent license agreement. We believe that this agreement and other commercial strategies will allow Dusa to maximize the value of this asset.”